In these PDX models, prolonged treatment with larotrectinib resulted in the outgrowth of tumours with a newly acquired BRAF-V600E mutation, thus replicating the development of this bypass mutation in the clinical setting and in this case report. The gene discussed is BRAF; the disease is neoplasm.